Rowen D, Lacey C
Department of Genito-Urinary Medicine, Royal South Hants Hospital, Southampton, United Kingdom.
Dermatol Clin. 1998 Oct;16(4):835-8. doi: 10.1016/s0733-8635(05)70056-5.
Much progress has been made over the past 10 years with regard to development of a vaccine active against HPV. Successful protection has been achieved in animal models using species-specific papillomaviruses; however, HPV diversity may delay the development of successful HPV vaccines, especially those designed as therapeutic vaccines for the treatment of HPV-induced carcinoma and high-grade dysplasia of the cervix. Difficulties arise with regard to assessment of efficacy of potential vaccines. The impetus for long-term studies on vaccine efficacy will initially stem from in vitro evidence of responsiveness to the vaccine. The time when a vaccine will have an impact on the prevalence of high-grade dysplasia and invasive cancer is still some way off.
在过去10年里，针对人乳头瘤病毒（HPV）开发有效疫苗方面已取得了很大进展。使用特定物种乳头瘤病毒在动物模型中已实现了成功保护；然而，HPV的多样性可能会延缓成功的HPV疫苗的开发，尤其是那些设计用于治疗HPV诱导的宫颈癌和宫颈高级别发育异常的治疗性疫苗。在评估潜在疫苗的疗效方面存在困难。对疫苗疗效进行长期研究的动力最初将源于对疫苗反应性的体外证据。疫苗对高级别发育异常和浸润性癌患病率产生影响的时间仍尚需时日。
